The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease

This study has been terminated.
Information provided by:
National Jewish Health Identifier:
First received: October 11, 2005
Last updated: September 24, 2014
Last verified: September 2014

October 11, 2005
September 24, 2014
November 1999
Not Provided
  • Spirometric response (FEV1)
  • Lung volumes such as residual volume (RV), thoracic gas volume, total lung capacity (TLC) and the RV/TLC ratio
Same as current
Complete list of historical versions of study NCT00238082 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease
The Effect of HFA-beclomethasone Dipropionate on Static Lung Volumes in COPD

This is an investigator-sponsored research study to evaluate if treatment with HFA-134a beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway "remodeling" or scarring in subjects with COPD. Approximately 20 subjects with COPD will participate for approximately 7 weeks, with 10 receiving an active (BDP) inhaler with HFA-134a and 10 receiving a placebo.

Not Provided
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Drug: HFA-134A Beclomethasone DIpropionate (QVAR)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2005
Not Provided

Inclusion Criteria:

  • COPD diagnosis
  • FEV1/FVC<70%
  • FEV1 50-80% predicted
  • Albuterol response of <12% and <200mL or methacholine PC20 > 8mg/mL
  • RV > 120% predicted
  • DLCO < 80%
  • smokers and nonsmokers
  • Lower age limit 45 years

Exclusion Criteria:

  • Asthma
  • Other chronic airway or parenchymal lung disease
  • Other comorbid illness (including but not limited to DM, MI or CAD-related intervention in 6 months, neurologic disease, syncope)
  • Use of any steroid (oral, IV, nasal, pulmonary) within 12 weeks
  • Use of theophylline, leukotriene modifiers within 12 weeks
  • Use of long-acting beta-agonists (formoterol, salmeterol) or anticholinergic (tiotropium)
45 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
National Jewish Health
Not Provided
Principal Investigator: Richard Martin, MD National Jewish Medical and Research Center faculty
National Jewish Health
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP